Latest Breaking News On - Evaluate early - Page 1 : comparemela.com

SPHERE Registry Data Highlight Racial, Ethnic Disparities in PAH Treatment, Outcomes

Data from the SPHERE registry revealed racial and ethnic discrepancies in disease severity, comorbidities, and outcomes experienced by patients with pulmonary arterial hypertension (PAH) receiving selexipag.

World health organizationHypertension conceptEvaluate earlyPulmonary arterial hypertension

Real-World Data Support Selexipag in the Treatment of PAH

Researchers used real-world data to further validate the use of selexipag in the management of pulmonary arterial hypertension (PAH).

World health organizationAlila medical mediaEvaluate earlyPulmonary arterial hypertension

Biomarker Predicts Survival in Pulmonary Arterial Hypertension

Plasma cell-free DNA, a marker of cellular injury, is elevated in patients with pulmonary arterial hypertension, correlates with disease severity, and predicts worse survival, new research shows.

New yorkUnited statesNational institutes of healthCarlos santos gallegoAmerican heart associationNational heartTufts medical centerBlood institute cardiovascular branchNational institutesAmerican heartDrug administration approvedAllegheny general hospitalEvaluate earlyMedscape cardiologyMount sinai hospitalNew york city

Janssen Showcases Commitment to Advancing Scientific Innovation in Pulmonary Arterial Hypertension (PAH) at CHEST 2021 Annual Meeting

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today 11 abstracts highlighting data from its pulmonary hypertension (PH).

United statesShelly orlacchioSean studerJen mcintyreNone of the janssen pharmaceutical companiesActelion pharmaceuticals us incDrug administrationJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonHoc analysis demonstrates association of risk statusActelion pharmaceuticals ltdExchange commissionAmerican college of chest physiciansBiomed research internationalCompanies of johnsonAmerican college

New Real-World Observational Analysis of UPTRAVI® (selexipag) Underscores the Importance of Risk Assessment for Treating Pulmonary Arterial Hypertension (PAH) Patients

New Real-World Observational Analysis of UPTRAVI® (selexipag) Underscores the Importance of Risk Assessment for Treating Pulmonary Arterial Hypertension (PAH) Patients
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Natalia salomaoWalker peasegoodJen mcintyreNick kimNone of the janssen pharmaceutical companiesHead of medical affairsActelion pharmaceuticals us incJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonActelion pharmaceuticals ltdExchange commissionUniversity of california san diegoEuropean respiratory societyActelion pharmaceuticals us ltdCompanies of johnsonEuropean society of cardiology